Myostatin Propeptide
The endogenous N-terminal prodomain of myostatin (GDF-8) that neutralizes mature myostatin to release the brakes on skeletal muscle growth.
Myostatin propeptide is the natural N-terminal prodomain cleaved from the myostatin (GDF-8) precursor. After cleavage it stays non-covalently bound to the mature myostatin dimer, holding it in an inactive latency-associated complex until BMP-1/tolloid metalloproteinases release the active growth factor. Recombinant versions act as endogenous-mechanism myostatin inhibitors, sequestering mature myostatin so it can no longer suppress muscle protein synthesis and satellite cell activity. It is a research-only compound with no human clinical, safety, or pharmacokinetic data.
Class
Recombinant myostatin (GDF-8) prodomain / endogenous myostatin inhibitor
Half-life
Unknown (not established in humans)
Routes
Subcutaneous, Intramuscular
Category
Growth Hormone & Performance
Researched benefits
What it's studied for
Myostatin inhibition
As the natural prodomain of GDF-8, the propeptide binds mature myostatin and holds it in an inactive complex, reducing myostatin signaling through the ActRIIB/Smad2/3 pathway. This is an endogenous-mechanism form of inhibition observed in rodent models.
Skeletal muscle hypertrophy
Transgenic overexpression of the propeptide in mice produced dramatic increases in skeletal muscle mass comparable to myostatin knockout, identifying it as a candidate molecule for promoting muscle growth (preclinical evidence).
Lean mass increase
By lifting myostatin's suppression of muscle protein synthesis and satellite cell activity, the propeptide is researched for its potential to increase lean muscle mass in animal models.
Strength gain
Increases in muscle mass driven by myostatin blockade are studied in the context of associated strength gains, though this remains preclinical and unquantified in humans.
Mechanism
How it works
Myostatin (GDF-8) is synthesized as a precursor protein. Proteolytic processing cleaves it into an N-terminal propeptide (prodomain) and a C-terminal mature growth factor that forms a disulfide-linked dimer. After cleavage, the propeptide remains non-covalently associated with the mature dimer, forming a latency-associated complex that keeps myostatin inactive.
The latent complex is activated when BMP-1/tolloid family metalloproteinases cleave the propeptide, releasing free mature myostatin. The active growth factor then engages ActRIIB receptors and signals through the Smad2/3 pathway to suppress skeletal muscle protein synthesis and satellite cell activity — acting as a negative regulator of muscle size.
Recombinant myostatin propeptide works by mimicking this natural inhibitory step: added propeptide sequesters mature myostatin in an inactive complex, lowering the amount of free myostatin available to signal. The result is reduced Smad2/3 inhibitory signaling and a corresponding release of the natural brake on muscle growth.
Rodent studies show that propeptide stability determines how much muscle growth occurs. A protease-resistant mutant propeptide, engineered to resist BMP-1/tolloid cleavage, caused significant increases in skeletal muscle mass when injected into adult mice — indicating that keeping the propeptide intact prolongs myostatin neutralization.
Evidence
Research & clinical studies (2)
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases
BMP-1/tolloid metalloproteinases cleave the myostatin propeptide to activate latent myostatin, and a protease-resistant mutant propeptide injected into adult mice caused significant increases in skeletal muscle mass, indicating propeptide stability is a key determinant of muscle growth regulation.
PMID 14671324Regulation of myostatin activity and muscle growth
Transgenic overexpression of the myostatin propeptide, follistatin, or a dominant-negative activin receptor IIB each produced dramatic increases in skeletal muscle mass comparable to myostatin knockout, identifying the propeptide as an endogenous myostatin inhibitor and muscle-growth candidate.
PMID 11459935Safety
Side effects & considerations
Contraindications & cautions
- Active cancer
- Prostate conditions
- Pregnancy
Myostatin propeptide carries a moderate risk profile in research contexts. No human adverse-event data exists because it has never been tested clinically in humans. The listed contraindications are precautionary considerations; consult a qualified healthcare professional before any use.
FAQ
Myostatin Propeptide — common questions
What is Myostatin Propeptide?
It is the endogenous N-terminal prodomain of the myostatin (GDF-8) precursor. After the mature myostatin dimer is cleaved off, the propeptide stays non-covalently bound to it, keeping it inactive in a latency-associated complex until BMP-1/tolloid metalloproteinases activate it. Recombinant propeptide can act as an endogenous-mechanism myostatin inhibitor by sequestering mature myostatin, reducing its suppression of muscle protein synthesis and satellite cell activity.
What is Myostatin Propeptide primarily studied for?
Myostatin inhibition, muscle hypertrophy, strength gain, and lean mass increase — all in preclinical animal models.
What does the research show?
Animal research found that BMP-1/tolloid metalloproteinases activate latent myostatin by cleaving the propeptide, and that a protease-resistant mutant propeptide injected into adult mice caused significant increases in skeletal muscle mass. A separate transgenic study showed propeptide overexpression increased muscle mass comparably to myostatin knockout.
Is Myostatin Propeptide approved or tested in humans?
No. It has no regulatory approval in any jurisdiction, has not been evaluated by the FDA, and has never been tested in human clinical trials. No human safety or pharmacokinetic data exists.
What are the side effects of Myostatin Propeptide?
There is no human adverse-event data. Reported precautionary contraindications include active cancer, prostate conditions, and pregnancy. It carries a moderate research risk profile.
How is Myostatin Propeptide administered in research?
Reported research routes are subcutaneous and intramuscular injection. There is no established or validated human dosing protocol.
